C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter A—GeneralPart 50—Protection of Human SubjectsSubpart B—Informed Consent of Human Subjects

21 C.F.R. § 50.25 (2026)

Elements of informed consent

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1984–2025 18citing cases
At a glance

Courts have cited this section in 18 opinions since 1984, 2 of them in the last five years.

(a) Basic elements of informed consent. In seeking informed consent, the following information shall be provided to each subject:

(1) A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental.

(2) A description of any reasonably foreseeable risks or discomforts to the subject.

(3) A description of any benefits to the subject or to others which may reasonably be expected from the research.

(4) A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject.

(5) A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained and that notes the possibility that the Food and Drug Administration may inspect the records.

(6) For research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained.

(7) An explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject.

(8) A statement that participation is voluntary, that refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled, and that the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.

(b) Additional elements of informed consent. When appropriate, one or more of the following elements of information shall also be provided to each subject:

(1) A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable.

(2) Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent.

(3) Any additional costs to the subject that may result from participation in the research.

(4) The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject.

(5) A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.

(6) The approximate number of subjects involved in the study.

(c) When seeking informed consent for applicable clinical trials, as defined in 42 U.S.C. 282(j)(1)(A), the following statement shall be provided to each clinical trial subject in informed consent documents and processes. This will notify the clinical trial subject that clinical trial information has been or will be submitted for inclusion in the clinical trial registry databank under paragraph (j) of section 402 of the Public Health Service Act. The statement is: “A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.”

(d) The informed consent requirements in these regulations are not intended to preempt any applicable Federal, State, or local laws which require additional information to be disclosed for informed consent to be legally effective.

(e) Nothing in these regulations is intended to limit the authority of a physician to provide emergency medical care to the extent the physician is permitted to do so under applicable Federal, State, or local law.

[46 FR 8951, Jan. 27, 1981, as amended at 76 FR 270, Jan. 4, 2011]
The 18 cases that cite 21 C.F.R. § 50.25 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENObermeier v. Nw. Mem'l Hosp., 2019 IL App (1st) 170553.
cites § 50.25 1×cited by 23 casesunpublished
Where it cites § 50.25
“( 21 C.F.R. § 50.25 (a)(1) (1993).) While we agree that generally a hospital is not in the best position to inform a patient of risks, here it is clear that Sherman Hospital undertook the responsibility to inform the plaintiff of the experimental nature of his surgery.”
Later courts cite it for
“general verdict rendered by the jury creates a presumption that the jury found in favor of a defendant on every defense raised' , as well as a presumption that 'all issues of fact upon which proof was offered were found in favor of the prevailing party' .” · 1 citing court
2
GREENDaum v. SpineCare Med. Grp., Inc., 52 Cal. App. 4th 1285 (Ct. App. 1997).
cites § 50.25 2×cited by 36 cases
Where it cites § 50.25
“( 21 C.F.R. § 50.25 (a)(1) (1996).) 9 They also require the subject to be given a copy of the written consent form.”
The case’s holding
When a duty to disclose is imposed by statute or regulation, a jury may not be restricted to expert testimony in determining the necessity, timing, or method of that disclosure.
3
GREENConnelly v. Iolab Corp., 927 S.W.2d 848 (Mo. 1996).
cites § 50.25 2×cited by 27 cases
Where it cites § 50.25
“The elements of informed consent are laid out in the federal regulations, 21 C.F.R. § 50.25 , and incorporated by reference into the IDA requirements for intraocular lenses.”
Later courts cite it for
“nothing in the fda regulations prohibits iolab from adding a warning to the label regarding unreasonably high complication rates.” · 2 citing courts
4
GREENSuthers v. Amgen, Inc., 372 F. Supp. 2d 416 (S.D.N.Y. 2005).
cites § 50.25 2×cited by 11 cases
Where it cites § 50.25
“One provision of the Common Rule, 21 C.F.R. § 50.25 (b)(2), anticipates that a study sponsor may seek the right to terminate a subject’s participation without his consent: When appropriate, one or more of the following elements of information shall also be provided to each…”
Later courts cite it for
“have shown neither a likelihood of success nor a sufficiently serious showing of merits to warrant the extraordinary relief of a preliminary injunction.” · 2 citing courts
5
GREENEstrada v. Jaques, 321 S.E.2d 240 (N.C. Ct. App. 1984).
cites § 50.25 1×cited by 74 cases
Where it cites § 50.25
“8,942 , 8,944, and 8,951 (1981), as codified at 21 C.F.R. § 50.25 (a)(1) (1984). The Supreme Court of Montana has recognized an informed consent cause of action where plaintiff alleged that the *650 procedure was experimental and that the physician did not disclose this, even…”
The case’s holding
An amended pleading relates back to the original filing date if the original complaint provides notice of the transactions or occurrences to be proved by the amendment.
Later courts cite it for
“usually depends on the facts and circumstances of each case and the procedural context of the orders appealed from.” · 11 citing courts
6
GREENKus v. Sherman Hosp., 644 N.E.2d 1214 (Ill. App. Ct. 2d Dist. 1995).
cites § 50.25 2×cited by 15 cases
Where it cites § 50.25
“) ( 21 C.F.R. § 50.25 (a)(1) (1993).) Part 50 also requires that informed consent be "documented by the use of a written consent form approved by the IRB and signed by the subject.”
The case’s holding
A hospital, as well as a physician, may be liable for a patient's defective consent to experimental intraocular lens implantation, and such consent claims are not preempted by federal device law.
Later courts cite it for
“a hospital, as well as a physician, may be held liable for a patient's defective consent in a case involving experimental intraceular lenses.” · 1 citing court
7
GREENLenahan v. Univ. of Chicago, 808 N.E.2d 1078 (Ill. App. Ct. 1st Dist. 2004).
cites § 50.25 1×cited by 20 cases
Where it cites § 50.25
“at they each bear an independent institutional responsibility to obtain informed consent from all human subjects in the clinical trial, and that such informed consents must comply with applicable Pood and Drug Administration (FDA) and Department of Health and Human Services…”
The case’s holding
A hospital may be liable for inadequate informed consent when it undertakes the responsibility to inform a patient of the experimental nature of a clinical trial.
8
GREENCtr. for Responsible Sci. v. Gottlieb, 346 F. Supp. 3d 29 (D.C. Cir. 2018).
cites § 50.25 1×cited by 6 cases
Where it cites § 50.25
“It contends that participants should be warned that testing drugs on laboratory animals - which generally precedes clinical trials involving humans - can be a poor predictor of safety and efficacy in human subjects.”
Later courts cite it for
“articulations of this rule abound, but they all focus on the same point: the organization's tasks must be impeded.” · 2 citing courts
9
GREENEvraets v. Intermedics Intraocular, Inc., 29 Cal. App. 4th 779 (Ct. App. 1994).
cites § 50.25 1×cited by 22 cases
Where it cites § 50.25
“) The elements of an informed consent are specified by regulation ( 21 C.F.R. § 50.25 (1994)), which is incorporated by reference into the IDE for intraocular devices.”
The case’s holding
Privity of contract is not required for a buyer to sue a manufacturer or seller for breach of an express warranty.
Later courts cite it for
“privity is not a requirement for actions based upon an express warranty” · 1 citing court
10
GREENCovey v. Surgidev Corp., 815 F. Supp. 1089 (N.D. Ohio 1993).
cites § 50.25 1×cited by 14 cases
Where it cites § 50.25
“21 C.F.R. § 50.25 . The plaintiff should also be informed that the procedure is, itself, a research study.”
Later courts cite it for
“to say that the regulations covering intraocular lenses are expansive would be an understatement” · 2 citing courts
11
GREENSita v. Long Island Jewish-Hillside Med. Ctr., 22 A.D.3d 743 (N.Y. App. Div. 2d Dep't 2005).
cites § 50.25 1×cited by 6 cases
Where it cites § 50.25
“Furthermore, because the injured plaintiff was not participating in a clinical investigation, FDA regulations did not require LIJ to obtain his informed consent or to disclose the regulatory status of the pedicle screw system (see 21 USC § 360j [g]; 21 CFR 50.25). Because as a…”
12
GREENMohr v. Targeted Genetics, Inc., 690 F. Supp. 2d 711 (C.D. Ill. 2010).
cites § 50.25 1×cited by 2 cases
Where it cites § 50.25
“Informed Consent Process ( 21 C.F.R. § 50.25 (a)(2)). Plaintiff challenges the FDA-approved consent form and related communications as “materially misleading and deceptive.”
13
NEUTRALChambers v. Osteonics Corp., 917 F. Supp. 624 (S.D. Ind. 1996).
cites § 50.25 2×cited by 1 case
Where it cites § 50.25
“See 21 C.F.R. § 50.25 . Second, they argue that the hip stem was defective and unreasonably dangerous because of weakness in the metal caused by negligent manufacturing.”
14
NO FLAGParkes v. NYU Langone Health, No. 1:24-cv-08099 (S.D.N.Y. June 9, 2025).
cites § 50.25 2×cited by 0 casesunknown
Where it cites § 50.25
“Plaintiff also invokes 21 C.F.R. § 50.25 , a regulation that applies “to clinical trials regulated by the Food and Drug Administration.”
15
NO FLAGCtr. for Responsible Sci. v. Gottlieb, No. 2017-2198 (D.D.C. Oct. 22, 2018).
cites § 50.25 1×cited by 0 cases
Where it cites § 50.25
“See 21 C.F.R. § 50.25 . Simply put, CRS believes that these disclosures are not enough.”
16
GREENUniv. Med. Ctr., Inc. v. Reagan Brooke Shwab, 628 S.W.3d 112 (Ky. 2021).
cites § 50.25 1×cited by 0 casesunknown
Where it cites § 50.25
“Title 21 C.F.R. § 50.25 outlines the information that must be contained within a valid informed consent form: (a) Basic elements of informed consent.”
The case’s holding
Kentucky's statutory informed consent standard applies to medical treatment administered within a clinical trial, and consent is judged by accepted medical practice and objective understanding of risks.
17
NO FLAGScheer, B. v. Burke, J., No. 1901 EDA 2013 (Pa. Super. Ct. Mar. 26, 2015).
cites § 50.25 1×cited by 0 casesunpublished
Where it cites § 50.25
“Burke, to provide a satisfactory informed consent document (ICD), as required by 21 CFR Part 50.25. The Investigator is responsible for creating the document and the IRB is responsible for approving it.”
18
GREENLenahan v. Univ. of Chicago, No. 1-02-2513, 1-02-2867 cons. Rel (Ill. App. Ct. 1st Dist. Mar. 31, 2004).
cites § 50.25 1×cited by 0 cases
Where it cites § 50.25
“at they each bear an independent institutional responsibility to obtain informed consent from all human subjects in the clinical trial, and that such informed consents must comply with applicable Food and Drug Administration (FDA) and Department of Health and Human Services…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198420042025

One bar per year. Tallest: 2 cases in 1996. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Ill. App. Ct.4Cal. Ct. App.2S.D.N.Y.2D.C. Cir.1D.D.C.1C.D. Ill.1S.D. Ind.1Ky.1

The 8 courts with the most citing cases, of 13 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com